LIVE, ATTENUATED RESPIRATORY SYNCYTIAL VIRUS

PROBLEM TO BE SOLVED: To provide live, attenuated respiratory syncytial viruses (RSV) useful as vaccines against RSV infection and/or the development of severe RSV-associated illnesses.SOLUTION: The live, attenuated RSV is identified by continuous passage of hRSV A strain (Merck strain 287). The att...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	YAGODICH MARY K, LIANG XIAOPING, CITRON MICHAEL P, DISTEFANO DANIEL J, KRAH DAVID L
Format:	Patent
Sprache:	eng
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	PROBLEM TO BE SOLVED: To provide live, attenuated respiratory syncytial viruses (RSV) useful as vaccines against RSV infection and/or the development of severe RSV-associated illnesses.SOLUTION: The live, attenuated RSV is identified by continuous passage of hRSV A strain (Merck strain 287). The attenuated virus is nonpathogenic and attenuated to some extent when administered to the subject, but substantially retains the antigenic and immunogenic properties of wild-type RSV. A method for inducing a protective immune response against the RSV infection in the subject's body includes a step of administering one or more of immunogenic composition including an attenuated RSV population and a pharmaceutically acceptable carrier.